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Background: Overexpression of miR-21 is a characteristic feature of patients with Mul-
tiple Sclerosis (MS) and is involved in gene regulation and the expression enhance-
ment of pro-inflammatory factors including IFNγ and TNF-α following stimulation of 
T-cells via the T Cell Receptor (TCR). In this study, a novel integrated bioinformatics 
analysis was used to obtain a better understanding of the involvement of miR-21 in 
the development of MS, its protein biomarker signatures, RNA levels, and drug inter-
actions through existing microarray and RNA-seq datasets of MS.  
 
Methods: In order to obtain data on the Differentially Expressed Genes (DEGs) in pa-
tients with MS and normal controls, the GEO2R web tool was used to analyze the 
Gene Expression Omnibus (GEO) datasets, and then Protein-Protein Interaction (PPI) 
networks of co-expressed DEGs were designed using STRING. A molecular network of 
miRNA-genes and drugs based on differentially expressed genes was created for T-
cells of MS patients to identify the targets of miR-21, that may act as important regu-
lators and potential biomarkers for early diagnosis, prognosis and, potential thera-
peutic targets for MS.  
 
Results: It found that seven genes (NRIP1, ARNT, KDM7A, S100A10, AK2, TGFβR2, 
and IL-6R) are regulated by drugs used in MS and miR-21. Finally, three overlapping 
genes (S100A10, NRIP1, KDM7A) were identified between miRNA-gene-drug network 
and nineteen genes as hub genes which can reflect the pathophysiology of MS.   
 
Conclusion: Our findings suggest that miR-21 and MS-related drugs can act synergisti-
cally to regulate several genes in the existing datasets, and miR-21 inhibitors have the 
potential to be used in MS treatment. 
 
 





Multiple Sclerosis (MS) is a common neurological 
disorder, which is more prevalent in women than men, 
and is identified by demyelination, chronic inflamma-
tion, and progressive neurological dysfunction 1,2. The 
etiology of this chronic inflammatory disorder is un-
clear; however, acute interstitial inflammation of 
nerves and the presence of multifocal sclerotic plaques 






system are common manifestations 3. A fundamental 
characteristic of MS is an antigen-specific autoimmune 
response 4. MS is a polygenic disease in which each 
gene has a small effect on the overall risk 5. Recent 
genome-wide association studies have identified about 
100 gene variants that are associated with a predisposi-
tion to MS. Most of these genes are considered to play 
a role in immunity 6. MicroRNAs have been proposed 
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as biomarkers for the early detection of MS 7,8. Mature 
miRNAs are ~18–22 nucleotide single-stranded endog-
enous RNAs that bind to their target sequence on 
mRNA and regulate gene expression 9. miRNAs are 
responsible for regulating the expression of more than 
60% of mammalian protein-coding genes 10. The ex-
pression profile of miRNA in MS patients has been 
studied and a large number of DEGs have been identi-
fied 11. For example, there is strong evidence that miR-
21 expression is up-regulated in MS patients compared 
with healthy controls 12. These miRNAs are highly 
conserved non-coding RNAs involved in post-trans-
criptional regulation 13. miRNAs appear to be poten-
tially useful as diagnostic biomarkers for MS, and it 
has been shown that the differential expression of these 
miRNAs is dependent on the time of onset and thera-
peutic stage. Recent studies have demonstrated that 
miRNAs may also have essential roles in MS patho-
genesis 14. It is, therefore, possible that they could be 
used as both diagnostic markers and therapeutic targets 
in MS (Table 1) 15,16. Although the function of miR-21 
has been relatively well studied, its role in the devel-
opment and progression of MS disease remains un-
clear. Satoh et al used proteomic profiling of MS brain 
lesions and analyzed the extracellular pathway to re-
veal the association between adhesion and integrin sig-
naling in the progression of chronic MS lesions 17. 
Freiesleben et al assessed microarray data of peripheral 
blood and integrated genes of MS patients using a con-
sensus method that determines the degree of agreement 
of inconsistent data 18. Studies performed using a varie-
ty of tissues such as brain lesions, and peripheral blood 
have been of relatively small cohort size and have not 
been replicated 18. It is worth pointing out that this 
study investigated microarray profiling of miRNA of 
appropriate size patient cohort, introduced the ap-
proach of the molecular network, and generated con-
sensus interaction network between differentially ex-
pressed miRNAs and genes in T-cells of untreated MS 
patients to identify dysregulated miRNAs and their 
target genes. To study the complex heterogeneity of 
multiple sclerosis for identifying MS-associated mo-
lecular functional networks in cells and dysregulated 
molecular mechanisms and pathways, integrative anal-
yses seem to be more efficient in identifying a potential 
therapeutic target than the assessment of individual 
genes 6,19,20. Bioinformatics analysis of gene expression 
profiling has recently been used to identify genetic 
alterations at RNA level, and transcription factors can 
be applied as biomarkers for human diseases such as 
MS 21. Bioinformatics analysis and systems biology 
can reveal molecular signatures comprising biomole-
cules at the protein level, drug, and RNA levels (miR-
NAs), and pathways have been used to obtain a more 
detailed understanding of the mechanisms involved in 
the pathogenesis of MS 22,23. In the current study, a new 
integrated bioinformatics analysis was used to obtain a 
more detailed understanding of the mechanistic impact 
of miR-21 in MS, its protein biomarker signatures, 
RNA levels (mRNAs, miRNAs), and drug interactions 
by using the existing microarray databases of MS. 
MiR-21 was selected based on the reported dysregula-
tion of this microRNA in MS 24. Online databases such 
as HMDD v3.2, miR2Disease, and PhenomiR were 
used to determine the importance of miR-21 in gene 
regulation in MS. This study aimed to create a molecu-
lar network of miRNA genes and drugs, based on dif-
ferentially expressed genes in T-cells of patients with 
MS, to identify the targets of miR-21, which act as 
important regulators and potential biomarkers in the 
early diagnosis, prognosis, and potential therapeutic 
targets for MS. 
 
Materials and Methods 
 
Data collection for gene expression analysis 
Using a consistent specific platform, microarray da-
tasets containing raw or normalized data were collected 
from the Gene Expression Omnibus (GEO) database. 
In order to collect comprehensive information, "multi-
ple sclerosis", "Homo sapiens", and study type (Ex- 
 
Table 1. An overview of the role of miR-21 in multiple sclerosis 
 
Authors Year miR-21 function 
Ma et al (25) 2014 
- Up-regulated in peripheral blood mononuclear cells of relapsing-remitting MS patients 
- Expansion of Th1 and Th17 cells 
- Regulates cell apoptosis and growth factors 
Lin et al (26) 2013 
- Increases the synthesis of IFN-γ and IL-17A by T-cells and suppresses apoptosis via programmed cell 
death protein 4 (PDCD4) 
- Is responsible for sustaining the effector phase in effector T-cells 
Piket et al  (27) 2019 - Up-regulated during active MS disease 
Tufekci et al (28) 2011 
- Upregulated after the activation of TLR4, myeloid cells, and macrophage 
- Inhibition in the expression of IL12a, PTEN, and PDCD4 
- Positive regulator of Foxp3 expression 
Sheedy et al (29) 2015 
- miR-21 in T-cell may also play an important role in self-tolerance regulation 
- Intrinsic miR-21 can also affect T-cell polarization 
Fenoglio et al  (30) 2011 
- Significantly increased expression of miR-21 in relapsing-remitting (RR) MS patients 
- Activation of CD4+ lymphocytes 
Muñoz-San Martín et al (12) 2019 
- Overexpressed in the CSF of Gd+ and PBMCs of relapsing-remitting MS patients 
- Associated with clinical disability 
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pression profiling by array) were selected as keywords 
for the search in the GEO database. Finally, data were 
obtained from 5 mRNA microarrays (GSE43592, 
GSE13732, GSE16461, GSE78244, and GSE81279). 
The overall analysis process for this study is shown in 
figure 1 and the frame used for the selection of these 
datasets is shown in figure 2. The selected datasets 
included gene expression profiling using microarray in 
T-cells of patients with MS but datasets in which pa- 
 
tients underwent treatment were excluded (Table 2). 
p<0.05 was set to determine significant expression 
changes. The study was expanded by adding in-silico 
predicted miRNAs based on available MS-related 
genes and pathways.   
 
Data preprocessing and analyzing of microarray 
The GEO2R interactive web tool (https://www.ncbi. 
nlm.nih.gov/geo/info/geo2r.html),  using the GEO que-
ry and limma R packages, was applied for the analysis 
and comparison of the expression profiles of MS sam-
ples with controls in order to identify significant differ-
ences in gene expression after GEO2R analysis and 
obtain a final list of significant genes based on p<0.05 
(Cut off ). The final results of the analysis of  DEGs for 
up- and down-regulated genes were obtained by using 
cut off values for  p<0.05 and log Fold Change (logFC) 
>1 or log FC<−1. According to this novel approach of 
combining microarray analysis and bioinformatics 
tools, common differentially expressed genes were 
identified and selected between the predicted targets of 
miR-21 and microarray datasets using a Venn diagram 
for showing T-cells from patients with MS. To investi-
gate the potential role of miR-21 in gene regulation in 
MS, publically available microarray datasets contain-
ing non-coding RNA of peripheral blood profiles of 
controls and patients were downloaded which corre-
sponded to platform specifications of GEO database 31. 
Studies in which patients were receiving therapy or in 
which samples were not obtained from blood, were 
excluded. At least seven replicates of the examined 
GSE31568 dataset containing each miRNA were 
measured, and the median of the replica was computed.  
To process the collected data more specifically, exper-
imentally validated targets of miR-21 were searched 
and used to construct a primary miRNA-mRNA-drug 
regulatory network. 
 
Prediction of miRNA target genes 
The predicted targets of miR-21 were obtained from 
the online functional annotation tool, mirDIP 4.1 (http: 
//ophid.utoronto.ca/mirDIP/),which provides 152 mil-
lion human microRNA–target predictions, collected 
across 28 different resources (BCmicrO , BiTargeting, 
CoMeTa, Cupid, DIANA, ElMMo3, GenMir++, Mi-
croRNA.org, miRBase, mirCoX, miRcode, miRDB, 
miRTar2GO, MAMI, MBStar, MirAncesTar, Mir- 
 
Figure 1. The bioinformatics flowchart used in the current study. 
DEGs: differentially expressed genes, PPI: protein-protein interaction, 
GEO: gene expression omnibus. 
Figure 2. Outline of the protocol used for the search of multiple scle-
rosis microarray datasets from the GEO database. 
Table 2. Characteristics of the five gene expression profiling datasets for multiple sclerosis in integrated bioinfor-
matics analysis 
 
GEO datasets Data Platform Controls MS patients Tissue Reference 
MicroRNA 
GSE31568 Normalized GPL9040 23 70 Peripheral blood cells (31) 
Genes 
GSE78244 Normalized GPL17077 14 14 CD4+T cells (32) 
GSE13732 Raw GPL570 37 28 CD4+T cells (33) 
GSE43591 Normalized GPL570 10 10 T cells (34) 
GSE16461 Normalized GPL1707 8 8 T cells (35) 
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MAP, MirSNP, MirTar, Mirza-G, MultiMiTar, PAC-
CMIT, PicTar, PITA, RepTar, RNA22, RNAhybrid, 
TargetRank, TargetScan, and TargetSpy) 37. Then, the 
target genes were aligned with the DEGs in MS, and 
this was used for further analysis. 
 
Independent validation by RNA-sequencing (RNA-seq) 
Independent validation of the 44 common genes as 
candidate key genes was derived by integrated micro-
array analysis results and miRNA targets and inde-
pendent samples of MS and healthy controls from 
RNA-seq experiment (GEO accession no. of GSE 
94266) were selected. The original experiment was 
designed to determine the Differentially Expressed 
Genes (DEGs) in MS patient versus healthy controls. 
Quality control of reads was analyzed using FastQC 
package (https://www.bioinformatics.babraham.ac.uk/ 
projects/fastqc/). Low quality reads and adaptor se-
quences were trim-med by the CLC Genomics Work-
bench 12.0.3 (QIAGEN, Germany). Mapping of short 
reads to the reference genome was performed using the 
CLC Genomics Workbench. Raw counts were obtained 
and used for Differential Expression (DE) analysis. 
The differential expression analysis was performed 
using DESeq2 and genes with p≤0.05 were defined as 
Differentially Expressed Genes (DEGs). 
 
Functional and pathway enrichment analysis 
The Gene Ontology (GO) enrichment analysis in-
cluding Biological Process (BP), Molecular Function 
(MF), and cellular component (CC), and the Kyoto 
encyclopedia of genes and genomes (KEGG) pathway 
enrichment analyses of common genes were carried out 
using the Enrichr database, which is a bioinformatics 
data platform consisting of an extensive biology 
knowledge database and analysis tools to align and 
explore significant biological information from large 
quantities of genes and protein collections 38. A p<0.05 
was used as the cut off criterion to determine the im-
portant pathways in which the genes are involved. 
 
PPI network construction  
The STRING (Search tool for the retrieval of inter-
acting genes) database (http://string-db.org/) was used 
for constructing common DEGs network by calculating 
the protein-protein interaction. 
 
Prediction of drug–gene interaction  
Drugs and their target genes were downloaded from 
the drug-gene interaction database (DGIdb v3.0, www. 
dgidb.org) 39,40. DGIdb normalizes content from 30 
different sources and provides access through an intui-
tive web user interface, Application Programming In-
terface (API), and public cloud-based server image 
40. In addition, Cytoscape software was applied to ex-
tend gene-drug interaction network. 
 
miRNA- mRNA-drug interaction network 
mRNA-miRNA and drug-based disease-associated 
regulatory network were assessed by using microarray 
datasets in order to identify the relationship between 
miR-21, differentially expressed genes, and well-
known drugs in MS. To create networks between 
miRNA-genes and drugs, common genes between 
DEGs and predicted miR-21 targets and related drugs 
were selected to obtain the intersection for creating 





Verification of miR-21 in MS 
In order to develop a miRNA gene-based disease-
associated network, data were collected by three differ-
ent methods to identify miRNAs associated with MS. 
MiR-21 was selected as a candidate biomarker in MS, 
based on previous findings regarding the role of miR-
21 in gene regulation in the etiology of MS. There was 
a statistically significant increase in expression of miR-
21 in the peripheral mononuclear cells of patients with 
Relapsing-Remitting (RR) MS compared to controls. 
For in silico analysis, the GSE31568 dataset contained 
23 MS samples and 70 control samples and based on 
GPL9040 platform (febit Homo Sapiens miRBase 
13.0), there was significantly up- and down-regulated 
miR-21 in peripheral blood cells (Table 3). 
 
Identification of differentially expressed genes (DEGs) in 
MS patients 
The five selected datasets were downloaded directly 
from GEO (https://www.ncbi.nlm.nih.gov/geo/) data-
base and analyzed using GEO2R. They were identified 
as 7502, 14776, 1840, 3927, 140 DEGs in GSE43591, 
GSE13732, GSE16461, GSE78244, and GSE81279 
and composed of up-and down-regulated expression 
based on criteria of log fold change >1 or <-1 and p< 
0.05 in MS as described in table 3 and figure 3. Genes 
of datasets that were differentially expressed in the 
same gene symbol or overlapping gene, at least two of 
the five datasets, were selected (Figure 3). In total, 680 
genes were obtained based on criteria of p<0.05 for 
carrying out the process analysis. Based on this novel 
approach, 44 genes (Table S1) were identified that 
overlapped as differentially expressed genes between 
the predicted target of miR-21 (994 genes) and micro-
array datasets (680 genes) using a Venn diagram (Ta-
ble S2, Figure 4).  
 
Identification of predicted target genes for miR-21 
In this study, 994 predicted genes as potential target  
 
Table 3. Microarray profiling for differential gene expression in T-cells 










GSE43591 7502 11 12 
GSE13732 14776 25 280 
GSE16461 1840 394 1159 
GSE78244 3927 154 37 
GSE81279 140 6 5 
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genes of miR-21 were obtained by using mirDIP. All 
genes shown in table S1 were predicted by mirDIP as 
targets of miR-21. Then, the target genes were aligned 
with the DEGs in MS, and this was used for further 
analysis. 
 
RNA sequence analysis 
Our analysis identified 6332 mRNAs that were sig-
nificantly differentially expressed between MS and 
healthy subjects (p<0.05), defined as differentially ex-
pressed genes. Then, overlapping genes between these 
genes and significant genes (44 common genes) and 18 
mRNAs (p<0.05, 1<│LogFC│<-1) were shown by 
microarray analysis (Figure 5). 
 
GO and KEGG pathway enrichment analyses of common 
genes 
GO and KEGG pathway enrichment analyses were 
performed for further investigation of the functional 
role of common DEGs and key pathways in MS pa-
tients. First of all, all common DEGs which had been 
submitted to the Enrichr online database were ana-
lyzed.  
As shown in table 4, signaling pathway analysis was 
performed using KEGG analysis for all common DEGs 
(44 genes). The results of KEGG enrichment analysis 
showed that the common DEGs were mainly enriched 
in inositol phosphate metabolism, sulfur metabolism, 
phosphatidylinositol signaling system, HIF-1 signaling 
pathway, Th17 cell differentiation, and thiamine me-
tabolism. For Cellular Component (CC), results of the 
top five GO terms (Table 5) reveal that 44 common 
DEGs were significantly enriched at microtubule mi-
nus-end, nuclear periphery, microtubule end, mitotic 
spindle pole, and membrane raft-mediated pathway 
(Table S3). For Biological Processes (BP), results of 
the top five GO enrichment analyses (Table 6) show  
 
Figure 5. Venn diagram represents the number of overlapping differ-
entially expressed genes between significant genes (n=6332) of RNA-
seq analysis, 44 common genes and 18 up- and down-regulated genes 
in multiple sclerosis disease. Validation of microarray result by RNA-
seq showed 19 and 7 overlapping genes with common genes and up- 
and down-regulated genes, respectively. 
Figure 3. A) Venn diagram represents the number of overlapping 
differentially down-regulated genes between datasets based on │Log 
FC│<-1 and p<0.05. Eleven overlapping genes, at least two datasets, 
were shown. B) Venn diagram represents the number of overlapping 
differentially up-regulated genes between datasets based on │Log 
FC│>1 and p<0.05. Seven overlapping genes, at least two datasets, 
were shown. C) differentially up- and down-regulated genes between 
datasets in MS patients versus healthy controls. 
Figure 4. A) 680 overlapping genes, at least three of the five GEO 
datasets, by Venn diagram with p<0.05. B) The common DEGs (44 
genes) as overlapping genes of the predicted target genes of miR-21, 
at least three of five datasets, using process analysis demonstrated by 
Venn diagram. miR: microRNA, DEGs: differentially expressed 
genes, MS: multiple sclerosis. 
Table 4. Significantly enriched KEGG signaling pathways of the 
differentially expressed genes identified in multiple sclerosis 
 
KEGG pathway p-value Genes 
Inositol phosphate  
metabolism 
0.011556016 PIKFYVE; IMPAD1 
Sulfur metabolism 0.019630393 IMPAD1 
Phosphatidylinositol signaling 
system 
0.020048578 PIKFYVE; IMPAD1 
HIF-1 signaling pathway 0.020429484 ARNT; IL6R 
Th17 cell differentiation 0.023180005 IL6R; TGFBR2 
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that they were significantly enriched and contained 
protein K63-linked deubiquitination, negative regula-
tion of protein depolymerization, protein K48-linked 
deubiquitination, cellular response to interleukin-6, and 
regulation of interleukin-6 production (Table S4). In 
addition, according to the results of the top five GO 
analyses shown in table 7, 44 common DEGs were 
significantly enriched in Molecular Function (MF), 
including Lys63-specific deubiquitinase activity, ubiq-
uitin-like protein-specific protease activity, thiol-de-
pendent ubiquitin-specific protease activity, thiol-de-
pendent ubiquitin hydrolase activity, and polyubiquitin 
modification-dependent protein binding (Table S5). 
 
Construction of protein-protein interaction network 
To assess the protein-protein interaction network, all 
DEGs were submitted to STRING. As shown in figure 
6, PPI network analysis introduced 44 nodes and 6 
edges for the common DEGs based on the PPI network 
modules and PPI enrichment with p-value of 0.638. 
 
Recognition of drugs related to common DEGs 
Next, an analysis of all the common DEGs using 
DGIdb v3.0 was carried out to detect affected genes 
associated with drugs in MS. An in-depth dissection of 
the effects of drugs on genes in MS was developed. 
These results demonstrated that seven genes in MS 
were targeted by drugs. According to table 8, multiple  
 
Table 5. Ten top GO enrichment analyses of 44 common differentially expressed genes (DEGs) with p<0.05 
 
Cellular component pathway ID p-value Genes 
Microtubule minus-end (GO:0036449) 1/31E-04 NIN; CAMSAP2 
Nuclear periphery (GO:0034399) 6/74E-04 ATF7; SMC1A; DCAF7 
Microtubule end (GO:1990752) 0/001062505 NIN; CAMSAP2 
Mitotic spindle pole (GO:0097431) 0/001374107 NIN; SMC1A 
Membrane raft (GO:0045121) 0/002276993 PIKFYVE; S100A10; TGFBR2 
Nucleolus (GO:0005730) 0/00344751 ATXN3; NIN; NRIP1; WDFY3; BRWD1; KDM7A 
Caveola (GO:0005901) 0/006755543 ATP2B4; TGFBR2 
Nuclear matrix (GO:0016363) 0/007474434 SMC1A; DCAF7 
Nucleoplasm part (GO:0044451) 0/012080201 PHF20; IMPAD1; ARNT; DCAF7 
Gamma-secretase complex (GO:0070765) 0/013129125 TMED10 
 
 
Table 6. Ten top biological process enrichment analyses of 44 common differentially expressed genes (DEGs) with p<0.05 
 
Biological process pathway ID p-value Genes 
Protein K63-linked deubiquitination (GO:0070536) 3/13E-05 ATXN3; TNFAIP3; BRCC3 
Negative regulation of protein depolymerization (GO:1901880) 8/76E-04 LIMA1; CAMSAP2 
Protein K48-linked deubiquitination (GO:0071108) 0/001162071 ATXN3; TNFAIP3 
Cellular response to interleukin-6 (GO:0071354) 0/001162071 ST3GAL6; IL6R 
Regulation of interleukin-6 production (GO:0032675) 0/003851281 TNFAIP3; IL6R 
Regulation of smooth muscle cell proliferation (GO:0048660) 0/004219716 TNFAIP3; IL6R 
Negative regulation of supramolecular fiber organization (GO:1902904) 0/006294875 LIMA1; CAMSAP2 
Hemopoiesis (GO:0030097) 0/01215973 RTKN2; TGFBR2 
Monoubiquitinated protein deubiquitination (GO:0035520) 0/013129125 ATXN3 
Regulation of epithelial to mesenchymal transition  




Table 7. Ten top molecular functions enrichment analyses of 44 common differentially expressed genes (DEGs) with p<0.05 
 
Molecular function pathway ID p-value Genes 
Lys63-specific deubiquitinase activity (GO:0061578) 1/62E-06 ATXN3; TNFAIP3; BRCC3 
Ubiquitin-like protein-specific protease activity (GO:0019783) 5/77E-04 ATXN3; TNFAIP3; BRCC3 
Thiol-dependent ubiquitin-specific protease activity (GO:0004843) 6/24E-04 ATXN3; TNFAIP3; BRCC3 
Thiol-dependent ubiquitinyl hydrolase activity (GO:0036459) 0/001088282 ATXN3; TNFAIP3; BRCC3 
Polyubiquitin modification-dependent protein binding (GO:0031593) 0/004033525 TNFAIP3; BRCC3 
Protein phosphatase 2B binding (GO:0030346) 0/013129125 ATP2B4 
Transforming growth factor beta-activated receptor activity (GO:0005024) 0/013129125 TGFBR2 
1-phosphatidylinositol-4-phosphate 5-kinase activity (GO:0016308) 0/013129125 PIKFYVE 
Interleukin-6 receptor binding (GO:0005138) 0/015300881 IL6R 
Adenylate kinase activity (GO:0004017) 0/015300881 AK2 
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drugs have regulatory and inhibitory roles in MS pa-
tients’ genes. 
 
Construction of regulatory miRNA-mRNA-drug network 
This approach was eventually used to develop a 
miRNA-mRNA-drug interaction network and identify 
key genes co-regulated by miR-21-5p and drugs. To 
illustrate the complex correlation between drugs and 
gene targets of miR-21, a layered network using Cyto-
scape v3.6.1 was created that can provide more de-
tailed information regarding these relationships. By 
integrated analyses, it was shown that 7 genes (NRIP1, 
ARNT, KDM7A, S100A10, AK2, TGFβR2, and IL-6R)  
 
were regulated by obtained drugs and miR-21; in fact, 
miR-21 and drugs can synergistically regulate path-





The involvement, functions, and complexity of 
miRNAs in autoimmune diseases are still unclear, es-
pecially in MS, due to the inadequate number of mi-
croarray expression profiles in MS studies 19. Overex-
pression of miR-21 in patients with MS may be a sig-
nature in regulating genes and enhanced expression of 
pro-inflammatory factors such as IFNγ and TNF-α af-
ter TCR stimulation. Up-regulation of miR-21 has been 
found in autoimmune diseases like IBD (Inflammatory 
Bowel Disease), SLE (Systemic Lupus Erythemato-
sus), and psoriasis. Our findings suggest that miR-21 
could be a target in clinical treatment for the inflamma- 
 
Figure 6. Protein-protein interaction of 44 common differentially 
expressed genes (DEGs) identified in multiple sclerosis by STRING. 
Table 8. Results of the analysis of common DEGs in MS and targeted drugs using DGIdb v3.0 
 
Drug Interaction type Gene Sources PMIDs Score 
ChEMBL 2164243  Inhibitor KDM7A Guide to Pharmacology None found 1 
Glycerin  N/A TGFBR2 DrugBank 17139284, 17016423 3 
Dexamethasone  N/A S100A10 NCI 10358078 2 
Tretinoin  N/A NRIP1 NCI 15632153, 14581481 3 
Etretinate  N/A NRIP1 NCI 15180561 2 
Tocilizumab  Antibody, inhibitor IL6R 
- My Cancer Genome TGD Clinical Trial  
- Guide to Pharmacology 
- ChEMBL interactions TEND  
- DrugBank  
- TTD 
16899109 8 
Sarilumab  Antagonist IL6R 
- ChEMBL interactions  
- TTD 
None found 2 
Thalidomide  N/A IL6R NCI 12515619 2 
Fluorouracil  N/A IL6R NCI 8888499 2 
Oprelvekin  Agonist IL6R Guide to Pharmacology None found 1 
Vobarilizumab  Antibody IL6R Guide to Pharmacology None found 1 
SA237  Antagonist IL6R ChEMBL interactions None found 1 
Sirukumab  N/A IL6R TDG Clinical Trial None found 1 
Hydrocortisone  N/A ARNT NCI 10048155 2 
ChEMBL 437508  N/A AK2 DrugBank 10592235, 17139284, 17016423 4 
 
 
Figure 7. miRNA-mRNA-drug interaction network constructed by 
Cytoscape; miR-21 regulates common DEGs and is related with 
genes affected by MS-associated drugs. Blue: common DEGs, Yel-
low: common DEGs affected by drugs, Pink: MS-associated drugs. 
15
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tory component of MS 24. Also, previous experimental 
studies have documented that T-cells transfected with 
miR-21 secreted  IFN-γ and TNF-α by affecting pro-
moter regions and have binding sites for several tran-
scriptional factors such as AP-1, STAT-3, MyD88, and 
NF-kB 29. MiR-21 directly inhibits the expression of 
PDCD4 that acts as a biomarker in pathogenic T-cell 
apoptosis and cell proliferation in human SLE. Over-
expression of miR-21 can lead to up-regulation of mul-
tiple genes which cause inflammation via activation of 
pathways such as NF-kB and MAPK 41. miR-21 indi-
rectly regulates Foxp3 expression 42. Induced miR-21, 
upon TCR activation, regulates several signaling path-
ways including ERK, AP-1 and AKT through negative 
feedback. Activation of these signaling pathways re-
sults in increased effector cells and decreases memory 
T-cell differentiation 43. Since predicting promoter re-
gion of pri-miR-21 is complex 29 and the exact roles of 
miR-21 are undetermined in MS disease, targeting 
miR-21 seems to be useful in developing a treatment 
based on the new approach. In the present study, pub-
licly available microarray databases were used to ana-
lyze significantly differentially expressed genes in MS 
patients and to identify molecular interactions between 
miR-21-mRNA and drugs for demonstrating biochemi-
cal mechanisms related to MS. Therefore, a miRNA- 
and a gene-drug network was created. Our network is 
different from previous studies in the literature because 
it is based on specific microarray datasets of T-cells in 
MS and pathway genes related to drugs. Also, our 
study identified 44 significantly up- and down-regulat-
ed common genes that may reflect the pathology and 
progression of MS. In this study, 44 new DEGs were 
found in T-cell MS datasets with overlap between at 
least three out of five microarray datasets. In the pre-
sent study, to identify 994 putative target genes of 
miR-21, miRDIP was used which contained 28 differ-
ent resources of functional annotation datasets. In addi-
tion, to obtain a final list of significant DEGs in T-cells 
from patients with and without MS, an analysis of five 
different datasets was performed, which identified 679 
MS-associated genes. Integrated analysis between pre-
dicted target genes of miR-21 and DEGs of datasets 
revealed 44 common DEGs as overlapping genes that 
were associated with the development and progression 
of MS disease. Our findings revealed 7 up-regulated 
and 15 down-regulated genes at the intersection of the 
44 common DEGs with five datasets that might be tar-
gets of miR-21 for the therapeutic approach. Therefore, 
the detection of putative target genes of miR-21 might 
identify how this miRNA controls different cell signal-
ing pathways and molecular mechanisms in MS dis-
ease. The results of GO annotation revealed that some 
genes, such as ATXN3, IL6R, AK2, ARNT, and TGFBR2 
are mutually and significantly effective between path-
ways related to MS disease. Also, the results of KEGG 
pathway enrichment analysis showed that the IL6R, 
AK2, ARNT, and TGFBR2 were the most significant 
genes in the HIF-1 signaling pathway, Th17 cell differ-
entiation, and thiamine metabolism pathways. Also, 
previous in vitro and ex vivo experimental studies have 
revealed that human Th17 cells were associated with 
disease activity and downstream pathways in the path-
ogenesis of autoimmunity 44 and they play distinctive 
effector roles  in MS patients 45. In addition, new drugs 
that targeted TH17 pathway such as Secukinumab (Co-
sentyx), human IgG1κ monoclonal antibody against 
IL-17A, can help in monitoring the disease activity and 
their potential role in inhibiting Th17 cell differentia-
tion as therapeutic targets in the treatment of autoim-
munity disorders 44 is confirmed based on findings in 
Experimental Autoimmune Encephalomyelitis (EAE) 
(MS disease model), and discovery of the biology and 
function of Th17 in encephalitogenicity 46. To discover 
the functions and roles of 44 common DEGs in MS 
disease, their correlation with MS-related drugs was 
assessed and regulatory and inhibitory effects of drugs 
on genes of MS patients were found. These results, 
based on the scoring criteria, can confirm the findings 
of GO and KEGG analysis that IL6R, AK2, TGFBR2, 
and ARNT genes are significantly effective in MS dis-
ease. These results indicate the potential therapeutic 
targets of DEGs in autoimmune MS disease. Through 
integrated analysis of both hybrid miRNA-mRNA drug 
network with the Cytoscape, this study identified a 
noticeable relation between miR-21 and genes, indicat-
ing that miR-21 could play pivotal roles in regulating 
pathways and phenotypes of MS. Interestingly, the 
regulation of  TGFBR2 by miR-21 has been demon-
strated by Luo et al similar to our analysis 24. Moreo-
ver, Meira et al have reported the significant down-
regulation of TGFBR2 expression in RRMS patients 
compared to healthy controls 47. In our analysis, ARNT 
genes were mainly involved in MS disease pathways, 
whereas Zorlu et al showed that this gene is consistent-
ly associated with MS in patients at the secondary pro-
gressive phase of the disease 48. AK2 as a novel apop-
totic pathway 49, the pivotal role of the AK2 gene in 
hematopoiesis, and its association with a pathway con-
trolling cell growth and survival were all explained by 
previous research 50. Although the exact role of AK2, 
ARNT, and ATXN3 in MS disease has not been stud-
ied yet, they be candidate therapies for MS disease. 
However, the effect of miR-21 on AK2, ATXN3, and 
ARNT has not been studied in MS disease and requires 
further investigation. miRNA is an ideal candidate for 
therapeutic targets due to the role of miRNAs in con-
trolling various gene expression in cancer and several 
other diseases, in particular autoimmune diseases 51. 
Nineteen genes among common genes were validated 
with RNA sequencing in this study. Finally, three over-
lapping genes (S100A10, NRIP1, KDM7A) were iden-
tified between miRNA-gene-drug network and nine-
teen genes as hub genes that may reflect the pathology 
of MS. It has been found that NRIP1 is involved in 
CNS-mediated neurophysiological processes and ad-
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ministration of Toll like-receptor ligands affects in-
flammatory potential in macrophages through their 
function as co-activators for NF-κB 52. He et al have 
mentioned that methylation is controlled by histone 
lysine methyltransferases (KMTs) and demethylases 
(KDMs) that possess strong substrate specificity and 
they have reported that histone lysine demethylases 
(KDMs) such as KMD7A play critical roles in the 
pathogenesis of MS 53. It has been identified that 
S100A10 as the specific marker of A2 astrocytes is 
essential for cell proliferation, membrane repair, and 
inhibition of cell apoptosis. Astrocytes play a key role 
in demyelinating diseases, like multiple sclerosis 54. 
Recent data demonstrate that artificial antisense miR-
NAs, such as Locked Nucleic Acid (LNA), bind to 
complementary RNA with high affinity and have sta-
bility and low toxicity without inducing the immune 
response 55; therefore, they could be applied to block 
their targeted oncomiRs to prevent the development of 
cancer. Also, antisense miRNAs as a gene silencing 
factor could significantly affect the prognosis of the 
disease 51. In particular, LNA against miR-122 repre-
sents an effective approach in the treatment of hepatitis 




The computational approach used in this study 
demonstrated the role of miR-21 as a regulator of the 
MS-related signaling pathways which can be a poten-
tial target for therapeutic modalities. Based on complex 
miRNA-mRNA interactions, genes targeted by many 
miRNAs have several sites for the same miRNA.  
However, the findings of the current study should be 
confirmed with available techniques such as real-time 
PCR and western blotting or luciferase assay. Since 
experimental validation of miRNA targets with labora-
tory techniques is expensive and cumbersome, the re-
sults of current bioinformatic approach would be an 
effective method for guiding in vivo and in vitro exper-
iments.  
An integrated miRNA-mRNA-drug network was 
developed to analyze predicted MS-associated target 
genes of miR-21, followed by functional enrichment 
assessment of the miR-21 targeted DEGs in MS pa-
tients. Based on the crucial effect of miR-21 on genes 
in MS patients, our research suggests applying miR-21 
inhibitors such as locked nucleic acid (LNA)-modified 
oligonucleotides that are known as stable, non-toxic 
drugs which do not induce an aberrant immune re-
sponse 56. Altogether, these findings can provide new 
insights into pathogenicity mechanisms of MS, thera-
peutic development, and interventions. Further studies 
are required to confirm the results of the present study 
in MS patients. 
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Table S1. 44 genes were identified that overlapped as differentially expressed genes 
between the predicted target of miR-21 and microarray datasets 
 
Gene symbol Gene symbol Gene symbol Gene symbol 
GATAD2B S100A10 AKAP7 BRCC3 
KDM7A RTKN2 ATP2B4 LIMA1 
TAGAP AKIRIN1 IRAK1BP1 CLDN8 
FAM13A ETNK1 SMC1A RBMS1 
ST3GAL6 EIF4EBP2 TMEM106B SNX13 
TGFBR2 WSB1 IL6R ATF7 
PIKFYVE NRIP1 TMED10 GPR180 
ZADH2 DNAJC16 PDLIM5 U2SURP 
DCAF7 WDR26 BRWD1 WDFY3 
TNFAIP3 NIN ATXN3 CAMSAP2 
PHF20 IMPAD1 ARNT AK2 
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CMKLR1 EPB41L3 PLBD1 
ARHGAP 
30 
PTBP3 ELOVL5 PIGS CTNNB1 ITPK1-AS1 KDSR BDP1 ZDHHC14 RUFY2 IFNGR1 
CYBB WSB1 CDC73 CENPO STAB1 NOP9 UBAP2L IFIH1 CCL28 BCL2L14 IMPAD1 SLC30A5 PDE4A HLA-DRB1 
CD44 WDR26 ITFG1 MNDA SSR2 FAM76B RPL23AP32 TOLLIP UBE4B TAF5L VPS16 OFCC1 CYP1B1 CD5 
TRAF3 FAM13A GAS7 F11 TPT1-AS1 SENP7 CD81 TICAM1 LYL1 MAST2 GPD1L LINC00487 BRWD1 IL18 
TLR2 NDE1 LINC01578 CTSS TRAF3IP3 NDUFC1 INPP5D PSMC2 WDR5 IKZF5 ADAMTS6 ZC3H10 PANX1 GPR183 
BCL10 FCGR2A TIMP2 LPCAT2 DMWD ITPRIPL2 MS4A7 RAF1 RANBP10 GIMAP8 MKKS EIF3K GPR180 ICAM4 




PITPNC1 WDFY3 MT1H CCDC134 MT2A ZFP41 GATAD2B ILF3 MFSD4B GPATCH2L 
MIR6791///
GPR108 
UBR2 SQSTM1 GDF7 
LINC01210 ZDHHC3 FAM208A AK2 FLT4 VTI1A XPO5 INIP UGP2 PLXNC1 CDK13 ARHGAP27 ZNF397 SMAD6 
PPHLN1 PSD4 SRSF5 SKIV2L RHBDD1 CFAP44 CCL2 CMPK2 APOBEC3G C10orf76 RPS6KA4 PDE12 ZNF148 NFATC4 
EPHA3 CAMSAP2 TMEM106B RSBN1L ARHGEF10L DNAJC16 ZNF160 PHF20 UCHL5 RPS2P45 
LOC10012
9034 
LOC100996385 CNOT4 ABCC3 






CEP250 IKZF1 SLC6A15 
EXOSC2 FBXL17 RTKN2 AARS2 TPP2 IP6K2 PART1 DCUN1D5 
LOC145783/// 
ZNF280D 
TRMT44 CD247 FBXO42 BRMS1 TPMT 
ACOX1 ATP2B4 U2SURP SRPK2 ZSCAN30 EIF5B SAMD1 NFYC MAP4K4 PKNOX1 GUSBP11 SFT2D3///WDR33 ARNT LINC00960 
ZNF441 ILDR1 PIKFYVE STK4 FAM13A-AS1 FLCN MST1 ZSCAN12 WNK1 C20orf196 CLCN3 CLCC1 BTRC PEX26 
FGFR2 SLC7A7 HNMT TGOLN2 CCDC141 DMXL2 POLQ MCF2L WAC ERI2 POLR2A CDC14A MAU2 B9D2 
LOC283788 CA5B NECTIN2 ATP6V1G1 CSTF3 
CSGAL-
NACT1 
CLDN8 ZNF775 LRIG2 PML SLC35C1 SSTR2 PPP2R1B TCOF1 









SLC8A1 SAT1 RAB35 THUMPD1 LY86 TMED10 MICAL3 CANT1 BET1L FLT3 KIR3DL3 SORT1 ARL10 HIF3A 




SNX25 TSPAN32 APPBP2 BCCIP RET TP53 PAK4 TRPM3 BIRC5 HNRNPM ZNF2 KIR2DL4 TBKBP1 CCNB1 
RAP1A NID1 CST3 RNASET2 MID1 AZI2 PURG TAF8 EIF3M TRIM44 GAK CELF1 P2RY12 NRXN1 
CD163 HCP5 OPA1 CCND2 LRRC25 INSIG1 TAB1 SNRPB2 POM121L12 SLC45A4 PAX5 DYNC1H1 PYHIN1 P2RY2 
TBL1X RAB14 VSTM4 ATP5C1 MS4A6A L3MBTL1 LMX1A PMS1 TTLL11 MTMR2 OSER1-AS1 ADGRG5 WDR78 SYK 
LOC1019272
04 
DYNC1LI2 ZNF107 TTPAL ATXN3 SOS1 CTNNA3 RAB28 DIDO1 IL16 ZNF641 BCAP29 MOGAT2 SOCS2 
ABI2 SMC1A CNOT7 BCAT1 CDC42 PACSIN2 CXCR4 GSE1 CARS TTN MYO10 IQSEC2 DOT1L PKHD1 
VPS53 FCGR1B CTSK LIG3 PER3 BTG1 GFI1 AP2A2 IL27RA TARP DLG3 NEK6 SEMA6A SGCD 




TUBA1B ARPC5 TMEM259 GNL3 AIF1 DNAH6 POLR1B KMT2C ARFGEF2 LRCH3 AP2A1 BRCC3 ISYNA1 STEAP3 
MROH2B ANXA6 TEPSIN MON1B ARHGEF40 NRIP1 MAF TMEM110 ZNF781 TTC9 PLEKHG3 KCND3 PPP1R12B KIF5A 
RANBP3 BRE-AS1 ZNF862 ANAPC4 TYW3 DNAJC3 CXCL1 ZADH2 EXOSC3 ABHD6 GLB1L2 LRRC42 BACE1 MEGF8 
ZNF322 ST3GAL6 HN1L TMX4 DDIT4 LIMA1 TNF EIF4EBP2 LOC389834 PRKCA PDGFB SNX13 NUP188 CORO6 
JAK3 SEPT9 HNRNPA2B1 KIAA1033 FAM198B SIRPB1 XCL1 MIR146A LIMS1 RDH10 LRPPRC TMEM185B NIN ATP5SL 
NCR1 TCEB3 CLEC7A AGTPBP1 S1PR1 MPP1 LCK 
LOC149684///
BPI 
SLC25A42 PTCD3 ZBTB7A UBE2L3 ZKSCAN5 SPIRE1 
C1R SLC26A11 VPS37A BRD4 PPME1 GFM1 BCL2L11 PTGDR KIAA1109 CTAGE5 DCAF7 LCMT2 PRB1 CCDC171 
CCNI MARCH7 PHACTR2 TNRC18 ACAD10 DIS3L2 TNFSF13B CDK12 IRAK1BP1 FAM129C RIMKLB FAM120AOS VPS18 ABLIM3 
OSBPL8 MT1X MAFB CPVL S100A10 TMEM41B CEBPB MTF1 C5orf63 FOXK2 ACPP NLRX1 ATP8A1 TGFBR2 
NR4A2 NUP50 AKR1C1 TRAM2 UBQLN1 NFAM1 IRAK4 LINC00894 ZNF717 ING5 ZNRF2 B3GALT2 MRPS27 SERPING1 
AP1S2 S100A8 GABBR2 
LOC15368
4 
POLR2C MLX IL6R NFKBID RNF216 POLR2J4 SCARB1 KIDINS220 UBTD2 CD74 
CDK1 TRAPPC10 IGF2R PPCDC DERL1 TAX1BP1 TAGAP OXR1 IKBKB SPTBN1 HACD3 DDX31 AKAP13 TIRAP 
SETDB1 RAP2B FCER1G SULF2 RASGRF2 FAM35A TNFAIP3 NAGS ST6GALNAC4 MED27 CIC DNAJC21 EFCAB13 HFE 
SAMSN1 HMGB2 APEX2 PPIEL CSF1R C11orf21 CXCL2 KEAP1 CNIH4 NCAM1 HTT DNM2 SSX2IP  
SEC14L1 PPP1R2 PFKFB4 KMT2B TMF1 COTL1 IFNAR2 GLYCTK GLS GPATCH2 TPGS2 IFT27 PDZD4  
KLF4 LRIF1 SREBF1 PPARD CRTAM MARCKS CD59 PTPN1 DCAF10 NFYA MRPS5 ZFAND5 TMED1  
AKIRIN1 MED17 PWWP2B STK10 MITF VCPKMT RELA LINC00528 C9orf40 MAGOHB STRBP RNF8 JAK2  
ANKRD26 SPOCK2 CNNM2 ZFAND1 LILRB2 NPEPPS CD48 NUP160 VRK3 SVIL PLAGL2 BAALC-AS2 CASP2  




TMTC1 TLK1 HNF4A ZNF91 LTB4R  
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Table S3. GO enrichment (Cellular component pathway) analyses of 44 common differentially expressed genes (DEGs) with p<0.05 
 
Cellular component pathway ID p-value Genes 
Microtubule minus-end (GO:0036449) 1.31E-04 NIN; CAMSAP2 
Nuclear periphery (GO:0034399) 6.74E-04 ATF7; SMC1A; DCAF7 
Microtubule end (GO:1990752) 0.001062505 NIN; CAMSAP2 
Mitotic spindle pole (GO:0097431) 0.001374107 NIN; SMC1A 
Membrane raft (GO:0045121) 0.002276993 PIKFYVE; S100A10; TGFBR2 
Nucleolus (GO:0005730) 0.00344751 ATXN3; NIN; NRIP1; WDFY3; BRWD1; KDM7A 
Caveola (GO:0005901) 0.006755543 ATP2B4; TGFBR2 
Nuclear matrix (GO:0016363) 0.007474434 SMC1A; DCAF7 
Nucleoplasm part (GO:0044451) 0.012080201 PHF20; IMPAD1; ARNT;DCAF7 
Gamma-secretase complex (GO:0070765) 0.013129125 TMED10 
Meiotic cohesin complex (GO:0030893) 0.013129125 SMC1A 
Mitotic spindle (GO:0072686) 0.014709297 NIN; SMC1A 
COPI-coated vesicle (GO:0030137) 0.017467967 TMED10 
Spindle pole (GO:0000922) 0.023180005 NIN; SMC1A 
Nuclear inclusion body (GO:0042405) 0.023941303 ATXN3 
Trans-Golgi network transport vesicle (GO:0030140) 0.032507623 TMED10 
NuRD complex (GO:0016581) 0.034637697 GATAD2B 
pericentriolar material (GO:0000242) 0.034637697 NIN 
CHD-type complex (GO:0090545) 0.034637697 GATAD2B 
Nuclear body (GO:0016604) 0.046308169 IMPAD1; ARNT; WDFY3; DCAF7 
Histone acetyltransferase complex (GO:0000123) 0.047322234 PHF20 
 
Table S4. Biological process enrichment analyses of 44 common differentially expressed genes (DEGs) with p<0.05 
 
Biological process pathway ID p-value Genes 
Protein K63-linked deubiquitination (GO:0070536) 3.13E-05 ATXN3; TNFAIP3; BRCC3 
Negative regulation of protein depolymerization (GO:1901880) 8.76E-04 LIMA1; CAMSAP2 
Protein K48-linked deubiquitination (GO:0071108) 0.001162071 ATXN3; TNFAIP3 
Cellular response to interleukin-6 (GO:0071354) 0.001162071 ST3GAL6; IL6R 
Regulation of interleukin-6 production (GO:0032675) 0.003851281 TNFAIP3; IL6R 
Regulation of smooth muscle cell proliferation (GO:0048660) 0.004219716 TNFAIP3; IL6R 
Negative regulation of supramolecular fiber organization (GO:1902904) 0.006294875 LIMA1; CAMSAP2 
Hemopoiesis (GO:0030097) 0.01215973 RTKN2; TGFBR2 
Monoubiquitinated protein deubiquitination (GO:0035520) 0.013129125 ATXN3 
Regulation of epithelial to mesenchymal transition involved in endocardial cushion for-
mation (GO:1905005) 
0.013129125 TGFBR2 
COPI-coated vesicle budding (GO:0035964) 0.013129125 TMED10 
Membrane raft assembly (GO:0001765) 0.013129125 S100A10 
Positive regulation of hormone metabolic process (GO:0032352) 0.013129125 ARNT 
COPI coating of Golgi vesicle (GO:0048205) 0.013129125 TMED10 
Regulation of T cell tolerance induction (GO:0002664) 0.013129125 TGFBR2 
Negative regulation of bone resorption (GO:0045779) 0.013129125 TNFAIP3 
Aggrephagy (GO:0035973) 0.013129125 WDFY3 
Response to DNA damage checkpoint signaling (GO:0072423) 0.013129125 SMC1A 
Protein deubiquitination involved in ubiquitin-dependent protein catabolic process 
(GO:0071947) 
0.013129125 TNFAIP3 
Golgi transport vesicle coating (GO:0048200) 0.013129125 TMED10 
Regulation of cardiac muscle hypertrophy in response to stress (GO:1903242) 0.013129125 ATP2B4 
Regulation of intracellular signal transduction (GO:1902531) 0.013642088 PHF20; FAM13A; TAGAP; AKAP7 
Negative regulation of nitric oxide biosynthetic process (GO:0045019) 0.015300881 ATP2B4 
Regulation of hormone biosynthetic process (GO:0046885) 0.015300881 ARNT 
Negative regulation of nitric oxide metabolic process (GO:1904406) 0.015300881 ATP2B4 
Response to misfolded protein (GO:0051788) 0.015300881 ATXN3 
Regulation of DNA endoreduplication (GO:0032875) 0.015300881 SMC1A 
Regulation of toll-like receptor 3 signaling pathway (GO:0034139) 0.015300881 TNFAIP3 
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Table S4. contd.  
 
Biological process pathway ID p-value Genes 
Regulation of transcription from RNA polymerase II promoter in response to oxidative 
stress (GO:0043619) 
0.017467967 ARNT 
Microtubule nucleation by microtubule organizing center (GO:0051418) 0.017467967 NIN 
Regulation of amyloid precursor protein catabolic process (GO:1902991) 0.017467967 TMED10 
Calcium ion import across plasma membrane (GO:0098703) 0.017467967 ATP2B4 
Response to epinephrine (GO:0071871) 0.017467967 ATP2B4 
Regulation of toll-like receptor 2 signaling pathway (GO:0034135) 0.017467967 TNFAIP3 
Histone H3-K36 demethylation (GO:0070544) 0.017467967 KDM7A 
Negative regulation of toll-like receptor 4 signaling pathway (GO:0034144) 0.017467967 TNFAIP3 
Positive regulation of alpha-beta T cell differentiation (GO:0046638) 0.017467967 TGFBR2 
Negative regulation of monooxygenase activity (GO:0032769) 0.017467967 ATP2B4 
Cellular response to epinephrine stimulus (GO:0071872) 0.017467967 ATP2B4 
Negative regulation of bone remodeling (GO:0046851) 0.017467967 TNFAIP3 
Calcium ion import into cytosol (GO:1902656) 0.017467967 ATP2B4 
Regulation of ERAD pathway (GO:1904292) 0.017467967 ATXN3 
Proteolysis involved in cellular protein catabolic process (GO:0051603) 0.017827712 ATXN3; TNFAIP3 
Protein deubiquitination (GO:0016579) 0.018853327 ATXN3; TNFAIP3; BRCC3 
B cell homeostasis (GO:0001782) 0.019630393 TNFAIP3 
Atrioventricular valve development (GO:0003171) 0.019630393 TGFBR2 
Microtubule anchoring at centrosome (GO:0034454) 0.019630393 NIN 
Golgi vesicle budding (GO:0048194) 0.019630393 TMED10 
Protein modification by small protein removal (GO:0070646) 0.01963191 ATXN3;TNFAIP3;BRCC3 
Membrane raft organization (GO:0031579) 0.021788169 S100A10 
Protein K11-linked deubiquitination (GO:0035871) 0.021788169 TNFAIP3 
Myeloid dendritic cell differentiation (GO:0043011) 0.021788169 TGFBR2 
Microtubule anchoring at microtubule organizing center (GO:0072393) 0.023941303 NIN 
Embryonic hemopoiesis (GO:0035162) 0.023941303 TGFBR2 
Positive regulation of mesenchymal cell proliferation (GO:0002053) 0.023941303 TGFBR2 
Negative regulation of cardiac muscle hypertrophy (GO:0010614) 0.023941303 ATP2B4 
Regulation of actin filament depolymerization (GO:0030834) 0.023941303 LIMA1 
Response to sterol (GO:0036314) 0.023941303 TGFBR2 
DNA repair (GO:0006281) 0.025350515 ATXN3; BRCC3; SMC1A 
Regulation of mesenchymal cell proliferation (GO:0010464) 0.026089806 TGFBR2 
Signal transduction involved in G2 DNA damage checkpoint (GO:0072425) 0.026089806 BRCC3 
Histone H3-K9 demethylation (GO:0033169) 0.026089806 KDM7A 
Vesicle budding from membrane (GO:0006900) 0.026089806 S100A10 
Response to interleukin-6 (GO:0070741) 0.026089806 ST3GAL6 
Positive regulation of vascular endothelial growth factor receptor signaling pathway 
(GO:0030949) 
0.026089806 ARNT 
Negative regulation of reactive oxygen species biosynthetic process (GO:1903427) 0.028233687 ATP2B4 
Pathway-restricted SMAD protein phosphorylation (GO:0060389) 0.028233687 TGFBR2 
Signal transduction involved in DNA damage checkpoint (GO:0072422) 0.028233687 BRCC3 
Positive regulation of ERAD pathway (GO:1904294) 0.028233687 ATXN3 
Regulation of cAMP-dependent protein kinase activity (GO:2000479) 0.028233687 ATP2B4 
Positive regulation of alpha-beta T cell proliferation (GO:0046641) 0.028233687 TGFBR2 
Branching involved in blood vessel morphogenesis (GO:0001569) 0.030372956 TGFBR2 
Interleukin-6-mediated signaling pathway (GO:0070102) 0.030372956 IL6R 
Histone H4-K16 acetylation (GO:0043984) 0.030372956 PHF20 
Regulation of Golgi organization (GO:1903358) 0.030372956 CAMSAP2 
Cardiac left ventricle morphogenesis (GO:0003214) 0.030372956 TGFBR2 
Myeloid dendritic cell activation (GO:0001773) 0.030372956 TGFBR2 
Regulation of defense response to virus (GO:0050688) 0.030372956 TNFAIP3 
Regulation of synapse organization (GO:0050807) 0.030372956 PDLIM5 
Regulation of calcineurin-NFAT signaling cascade (GO:0070884) 0.030372956 ATP2B4 
Cytoskeleton organization (GO:0007010) 0.031356737 RTKN2; BRWD1 
Atrioventricular valve morphogenesis (GO:0003181) 0.032507623 TGFBR2 
Response to cholesterol (GO:0070723) 0.032507623 TGFBR2 
Selective autophagy (GO:0061912) 0.032507623 WDFY3 
Histone H4-K8 acetylation (GO:0043982) 0.032507623 PHF20 
Phosphatidylethanolamine biosynthetic process (GO:0006646) 0.032507623 ETNK1 
Embryonic cranial skeleton morphogenesis (GO:0048701) 0.032507623 TGFBR2 
Negative regulation of interleukin-2 production (GO:0032703) 0.032507623 TNFAIP3 
Endocardial cushion morphogenesis (GO:0003203) 0.032507623 TGFBR2 
Positive regulation of glycolytic process (GO:0045821) 0.032507623 ARNT 
Mitotic sister chromatid cohesion (GO:0007064) 0.032507623 SMC1A 
Response to X-ray (GO:0010165) 0.032507623 BRCC3 
Negative regulation of DNA-dependent DNA replication (GO:2000104) 0.032507623 SMC1A 
Histone H4-K5 acetylation (GO:0043981) 0.032507623 PHF20 
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Table S4. contd. 
 
Biological process pathway ID p-value Genes 
Negative regulation of translational initiation (GO:0045947) 0.034637697 EIF4EBP2 
Sialylation (GO:0097503) 0.034637697 ST3GAL6 
Regulation of toll-like receptor 4 signaling pathway (GO:0034143) 0.034637697 TNFAIP3 
Ruffle organization (GO:0031529) 0.034637697 LIMA1 
mRNA transcription from RNA polymerase II promoter (GO:0042789) 0.034637697 ARNT 
Regulation of cell cycle phase transition (GO:1901987) 0.034637697 ATP2B4 
Positive regulation of response to endoplasmic reticulum stress (GO:1905898) 0.034637697 ATXN3 
Positive regulation of focal adhesion assembly (GO:0051894) 0.036763188 S100A10 
Septin ring organization (GO:0031106) 0.036763188 RTKN2 
Negative regulation of B cell activation (GO:0050869) 0.036763188 TNFAIP3 
Regulation of small GTPase mediated signal transduction (GO:0051056) 0.038004345 FAM13A; TAGAP 
Negative regulation of microtubule depolymerization (GO:0007026) 0.038884106 CAMSAP2 
Membrane lipid metabolic process (GO:0006643) 0.038884106 ST3GAL6 
Regulation of microtubule polymerization or depolymerization (GO:0031110) 0.038884106 CAMSAP2 
Positive regulation of carbohydrate metabolic process (GO:0045913) 0.038884106 ARNT 
Regulation of amyloid-beta formation (GO:1902003) 0.038884106 TMED10 
Regulation of chemokine production (GO:0032642) 0.038884106 IL6R 
Acute-phase response (GO:0006953) 0.038884106 IL6R 
Negative regulation of calcium-mediated signaling (GO:0050849) 0.038884106 ATP2B4 
Cell-cell adhesion via plasma-membrane adhesion molecules (GO:0098742) 0.038994651 CLDN8; TGFBR2 
Regulation of mitotic spindle assembly (GO:1901673) 0.04100046 SMC1A 
Cellular response to interleukin-7 (GO:0098761) 0.04100046 BRWD1 
Regulation of protein kinase A signaling (GO:0010738) 0.04100046 AKAP7 
Purine ribonucleoside bisphosphate metabolic process (GO:0034035) 0.04100046 IMPAD1 
Histone deubiquitination (GO:0016578) 0.04100046 BRCC3 
Negative regulation of lymphocyte activation (GO:0051250) 0.04100046 TNFAIP3 
Positive regulation of adherens junction organization (GO:1903393) 0.04100046 S100A10 
Protein heterotetramerization (GO:0051290) 0.04100046 S100A10 
Calcium ion transport into cytosol (GO:0060402) 0.04100046 ATP2B4 
Interleukin-7-mediated signaling pathway (GO:0038111) 0.04100046 BRWD1 
Negative regulation of innate immune response (GO:0045824) 0.043112259 TNFAIP3 
Regulation of vacuole organization (GO:0044088) 0.043112259 PIKFYVE 
Cellular response to estradiol stimulus (GO:0071392) 0.043112259 NRIP1 
Phosphatidylethanolamine metabolic process (GO:0046337) 0.043112259 ETNK1 
Calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules 
(GO:0016338) 
0.043112259 CLDN8 
mRNA transcription (GO:0009299) 0.045219514 ARNT 
Dendritic cell differentiation (GO:0097028) 0.045219514 TGFBR2 
Regulation of interleukin-2 production (GO:0032663) 0.045219514 TNFAIP3 
Ventricular septum morphogenesis (GO:0060412) 0.045219514 TGFBR2 
Cellular response to misfolded protein (GO:0071218) 0.045219514 ATXN3 
Histone lysine demethylation (GO:0070076) 0.045219514 KDM7A 
Embryonic skeletal system morphogenesis (GO:0048704) 0.045219514 TGFBR2 
Cellular macromolecule biosynthetic process (GO:0034645) 0.04668864 EIF4EBP2; ARNT; RBMS1 
Regulation of microtubule depolymerization (GO:0031114) 0.047322234 CAMSAP2 
Regulation of vascular endothelial growth factor receptor signaling pathway 
(GO:0030947) 
0.047322234 ARNT 
Regulation of bone resorption (GO:0045124) 0.047322234 TNFAIP3 
Positive regulation of erythrocyte differentiation (GO:0045648) 0.047322234 ARNT 
Outflow tract septum morphogenesis (GO:0003148) 0.047322234 TGFBR2 
Negative regulation of intracellular signal transduction (GO:1902532) 0.048879819 ATP2B4; TNFAIP3 
Positive regulation of ATP metabolic process (GO:1903580) 0.049420428 ARNT 
Cellular response to catecholamine stimulus (GO:0071870) 0.049420428 ATP2B4 
Positive regulation of cell junction assembly (GO:1901890) 0.049420428 S100A10 
Membrane assembly (GO:0071709) 0.049420428 S100A10 
Regulation of dendritic spine morphogenesis (GO:0061001) 0.049420428 PDLIM5 
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Table S5. Molecular functions enrichment analyses of 44 common differentially expressed genes (DEGs) with p<0.05 
 
Molecular function pathway ID p-value Genes 
Lys63-specific deubiquitinase activity (GO:0061578) 1.62E-06 ATXN3; TNFAIP3; BRCC3 
Ubiquitin-like protein-specific protease activity (GO:0019783) 5.77E-04 ATXN3; TNFAIP3; BRCC3 
Thiol-dependent ubiquitin-specific protease activity (GO:0004843) 6.24E-04 ATXN3; TNFAIP3; BRCC3 
Thiol-dependent ubiquitinyl hydrolase activity (GO:0036459) 0.001088282 ATXN3; TNFAIP3; BRCC3 
Polyubiquitin modification-dependent protein binding (GO:0031593) 0.004033525 TNFAIP3; BRCC3 
Protein phosphatase 2B binding (GO:0030346) 0.013129125 ATP2B4 
Transforming growth factor beta-activated receptor activity (GO:0005024) 0.013129125 TGFBR2 
1-phosphatidylinositol-4-phosphate 5-kinase activity (GO:0016308) 0.013129125 PIKFYVE 
Interleukin-6 receptor binding (GO:0005138) 0.015300881 IL6R 
Adenylate kinase activity (GO:0004017) 0.015300881 AK2 
Beta-galactoside (CMP) alpha-2,3-sialyltransferase activity (GO:0003836) 0.015300881 ST3GAL6 
Type I transforming growth factor beta receptor binding (GO:0034713) 0.017467967 TGFBR2 
Aryl hydrocarbon receptor binding (GO:0017162) 0.017467967 ARNT 
Glucocorticoid receptor binding (GO:0035259) 0.019630393 NRIP1 
Histone demethylase activity (H3-K36 specific) (GO:0051864) 0.019630393 KDM7A 
Phosphatidylinositol binding (GO:0035091) 0.020429484 SNX13;WDFY3 
Lys48-specific deubiquitinase activity (GO:1990380) 0.021788169 ATXN3 
Microtubule minus-end binding (GO:0051011) 0.021788169 CAMSAP2 
Eukaryotic initiation factor 4E binding (GO:0008190) 0.021788169 EIF4EBP2 
Histone acetyltransferase activity (H4-K16 specific) (GO:0046972) 0.021788169 PHF20 
Histone acetyltransferase activity (H4-K5 specific) (GO:0043995) 0.021788169 PHF20 
Histone acetyltransferase activity (H4-K8 specific) (GO:0043996) 0.021788169 PHF20 
Nitric-oxide synthase binding (GO:0050998) 0.023941303 ATP2B4 
Histone demethylase activity (H3-K9 specific) (GO:0032454) 0.028233687 KDM7A 
Phosphatidylinositol phosphate 5-phosphatase activity (GO:0034595) 0.028233687 PIKFYVE 
Transmembrane receptor protein serine/threonine kinase activity (GO:0004675) 0.030372956 TGFBR2 
Calcium-transporting ATPase activity (GO:0005388) 0.030372956 ATP2B4 
1-phosphatidylinositol binding (GO:0005545) 0.030372956 WDFY3 
Phosphatidylinositol-3,5-bisphosphate phosphatase activity (GO:0106018) 0.032507623 PIKFYVE 
Phosphatidylinositol phosphate kinase activity (GO:0016307) 0.032507623 PIKFYVE 
Nucleotidase activity (GO:0008252) 0.034637697 IMPAD1 
H4 histone acetyltransferase activity (GO:0010485) 0.036763188 PHF20 
GTP-Rho binding (GO:0017049) 0.036763188 RTKN2 
Protein kinase A regulatory subunit binding (GO:0034237) 0.038884106 AKAP7 
Transforming growth factor beta binding (GO:0050431) 0.04100046 TGFBR2 
Cadherin binding involved in cell-cell adhesion (GO:0098641) 0.04100046 PDLIM5 
Mitogen-activated protein kinase binding (GO:0051019) 0.043112259 ATF7 
K63-linked polyubiquitin modification-dependent protein binding (GO:0070530) 0.043112259 TNFAIP3 
Sialyltransferase activity (GO:0008373) 0.045219514 ST3GAL6 
Protein binding involved in cell-cell adhesion (GO:0098632) 0.045219514 PDLIM5 
ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism 
(GO:0015662) 0.047322234 ATP2B4 
Actinin binding (GO:0042805) 0.047322234 PDLIM5 
Nucleotide kinase activity (GO:0019201) 0.049420428 AK2 
 
 
